TY - JOUR
T1 - Children's Oncology Group 2023 blueprint for research
T2 - Adolescent and young adult oncology
AU - COG Adolescent and Young Adult Oncology Discipline Committee
AU - Roth, Michael E.
AU - Grimes, Allison C.
AU - Reed, Damon R.
AU - Weiss, Aaron R.
AU - Mittal, Nupur
AU - Parsons, Susan K.
AU - Freyer, David R.
N1 - Publisher Copyright:
© 2023 Wiley Periodicals LLC.
PY - 2023/9
Y1 - 2023/9
N2 - Over the past few decades, 5-year cancer survival has steadily improved for all adolescents and young adults (AYA, 15–39 years at diagnosis) combined. While encouraging, this progress simultaneously highlights a compelling need for improving survival in higher risk AYA subsets and for addressing health outcomes and health-related quality of life (HRQoL) among long-term survivors. The Children's Oncology Group (COG), in collaboration with the National Cancer Institute (NCI) and the adult network groups within the NCI National Clinical Trials Network (NCTN), has developed a large and growing portfolio of therapeutic AYA cancer clinical trials to identify optimal treatment approaches for common AYA cancers. Additional initiatives, led by the COG AYA Oncology Discipline Committee for increasing collaboration between the COG and the adult network groups, optimizing AYA clinical trial enrollment, and standardizing the assessment of HRQoL, have been highly successful to date. Further, NCTN-wide collaborations are currently underway focused on improving survival for AYA malignancies with poor prognosis and, through development of supportive care and care delivery trials, reducing the short- and long-term toxicity caused by cancer treatment. Leveraging the research infrastructure within the NCTN and the NCI Community Oncology Research Program, the COG will continue to champion meaningful advancements in health and survival for AYAs with cancer.
AB - Over the past few decades, 5-year cancer survival has steadily improved for all adolescents and young adults (AYA, 15–39 years at diagnosis) combined. While encouraging, this progress simultaneously highlights a compelling need for improving survival in higher risk AYA subsets and for addressing health outcomes and health-related quality of life (HRQoL) among long-term survivors. The Children's Oncology Group (COG), in collaboration with the National Cancer Institute (NCI) and the adult network groups within the NCI National Clinical Trials Network (NCTN), has developed a large and growing portfolio of therapeutic AYA cancer clinical trials to identify optimal treatment approaches for common AYA cancers. Additional initiatives, led by the COG AYA Oncology Discipline Committee for increasing collaboration between the COG and the adult network groups, optimizing AYA clinical trial enrollment, and standardizing the assessment of HRQoL, have been highly successful to date. Further, NCTN-wide collaborations are currently underway focused on improving survival for AYA malignancies with poor prognosis and, through development of supportive care and care delivery trials, reducing the short- and long-term toxicity caused by cancer treatment. Leveraging the research infrastructure within the NCTN and the NCI Community Oncology Research Program, the COG will continue to champion meaningful advancements in health and survival for AYAs with cancer.
KW - adolescent and young adult oncology
KW - cancer care delivery
KW - clinical trials
UR - http://www.scopus.com/inward/record.url?scp=85165182131&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85165182131&partnerID=8YFLogxK
U2 - 10.1002/pbc.30564
DO - 10.1002/pbc.30564
M3 - Article
C2 - 37439574
AN - SCOPUS:85165182131
SN - 1545-5009
VL - 70
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
IS - S6
M1 - e30564
ER -